**Supplementary Table 3. Univariate and multivariate analysis of factors for overall response rate of first-line chemotherapy**

| Characteristic | Univariate analysis | | Multivariate analysis | |
| --- | --- | --- | --- | --- |
| | OR (95% CI) | *p* value | OR (95% CI) | *p* value |
| Age ≥ 84 yr | 1.95 (0.75–5.08) | 0.169 | | |
| Sex, female | 1.17 (0.49–2.74) | 0.724 | | |
| ECOG PS > 2 | 2.14 (0.83–5.55) | 0.116 | | |
| CCI > 4 | 1.02 (0.40–2.56) | 0.973 | | |
| ISS III | 1.14 (0.46–2.85) | 0.775 | | |
| R-ISS III | 1.43 (0.56–3.63) | 0.454 | | |
| Hemoglobin < 10 g/dL | 1.69 (0.62–4.61) | 0.301 | | |
| Bone disease | 2.86 (1.09–7.53) | 0.033 | 2.93 (0.88–9.73) | 0.079 |
| Calcium > 11 mg/dL | 2.65 (0.27–26.57) | 0.407 | | |
| Creatinine > 2 mg/dL | 1.61 (0.57–4.61) | 0.372 | | |
| Platelet < $100 \times 10^9$/L | 1.43 (0.49–4.14) | 0.515 | | |
| Albumin < 3.5 g/dL | 1.59 (0.65–3.89) | 0.310 | | |
| LDH elevation | 1.64 (0.68–3.92) | 0.269 | | |
| High-risk cytogenetic abnormalities | 3.47 (1.09–11.05) | 0.036 | 2.59 (0.75–8.94) | 0.132 |
| 1st chemotherapy | | 0.113 | | |
| Bortezomib-based | 1 | | | |
| Lenalidomide-base | 2.41 (0.89–6.53) | | | |
| Alkylating agent-based | 2.76 (0.86–8.80) | | | |

OR, odds ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; CCI, Charlson comorbidity index; ISS, International Staging System; R-ISS, Revised International Staging System; LDH, lactate dehydrogenase.